Logo image
Atovaquone Compared with Dapsone for the Prevention of Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both
Journal article   Peer reviewed

Atovaquone Compared with Dapsone for the Prevention of Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

Wafaa M El-Sadr, Robert L Murphy, Teresa McCabe Yurik, Roberta Luskin-Hawk, Tony W Cheung, Henry H Balfour, Robert Eng, Thomas M Hooton, Thomas M Kerkering, Malte Schutz, …
The New England journal of medicine, Vol.339(26), pp.1889-1895
12/24/1998
DOI: 10.1056/NEJM199812243392604
PMID: 9862944

View Online

Abstract

The prevention of Pneumocystis carinii pneumonia has had a substantial influence on the course of human immunodeficiency virus (HIV) disease. 1 , 2 Although trimethoprim–sulfamethoxazole is the treatment of choice for prophylaxis against P. carinii pneumonia, intolerance often limits its use and makes it necessary to use alternative regimens. 3 Dapsone, alone or in combination with pyrimethamine, is a commonly recommended prophylactic regimen for P. carinii pneumonia in patients who cannot tolerate trimethoprim–sulfamethoxazole. 4 Dapsone plus pyrimethamine has been shown to be superior to aerosolized pentamidine for the prevention of toxoplasmosis. 5 However, dapsone has limitations: it is less effective than trimethoprim–sulfamethoxazole for the prevention . . .

Details

Logo image